Literature DB >> 8862427

Expression of human foamy virus reverse transcriptase involves a spliced pol mRNA.

I Jordan1, J Enssle, E Güttler, B Mauer, A Rethwilm.   

Abstract

In human foamy virus (HFV) the reverse transcriptase is expressed independently of the Gag protein as a 127-kDa Pol precursor molecule. Evaluating the mechanism of Pol expression we identified a spliced mRNA which uses the main 5' splice donor and a splice acceptor site located in the gag gene. The significance of this spliced transcript for HFV Pol expression was studied by constructing a virus with a mutated splice acceptor site. This virus was unable to express detectable Pol proteins after transient transfection. Replication of the mutant was studied by a sensitive assay based on HFV transactivator-stimulated expression of an integrated lacZ gene under control of the HFV long terminal repeat. Whereas in the first 2 weeks after transfection the mutant replicated 3 to 5 order of magnitude less well than wild-type virus, extracellular titers obtained thereafter were similar to those of wild-type virus. This increase in replication competence was accompanied by a reversion of the mutated splice acceptor site. The results underlined the importance of the spliced pol transcript for HFV replication and pointed to a second mechanism of Pol expression. Indicator gene assays suggest that this other mechanism is likely to be a transactivator-dependent cryptic promoter in the gag gene which gives rise to Pol-encoding transcripts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862427     DOI: 10.1006/viro.1996.0534

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging.

Authors:  M Heinkelein; J Thurow; M Dressler; H Imrich; D Neumann-Haefelin; M O McClure; A Rethwilm
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  The R region found in the human foamy virus long terminal repeat is critical for both Gag and Pol protein expression.

Authors:  R A Russell; Y Zeng; O Erlwein; B R Cullen; M O McClure
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 3.  Molecular biology of foamy viruses.

Authors:  Axel Rethwilm
Journal:  Med Microbiol Immunol       Date:  2010-05-06       Impact factor: 3.402

4.  Identification of domains in gag important for prototypic foamy virus egress.

Authors:  Gillian S Patton; Stephen A Morris; Wayne Chung; Paul D Bieniasz; Myra O McClure
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  RNA and protein requirements for incorporation of the Pol protein into foamy virus particles.

Authors:  Katrin Peters; Tatiana Wiktorowicz; Martin Heinkelein; Axel Rethwilm
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle.

Authors:  J Enssle; N Fischer; A Moebes; B Mauer; U Smola; A Rethwilm
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Human foamy virus reverse transcription that occurs late in the viral replication cycle.

Authors:  A Moebes; J Enssle; P D Bieniasz; M Heinkelein; D Lindemann; M Bock; M O McClure; A Rethwilm
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 8.  Foamy viruses are unconventional retroviruses.

Authors:  M L Linial
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Regulation of foamy virus protease activity by viral RNA: a novel and unique mechanism among retroviruses.

Authors:  Maximilian J Hartl; Jochen Bodem; Fabian Jochheim; Axel Rethwilm; Paul Rösch; Birgitta M Wöhrl
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

10.  Pregenomic RNA is required for efficient incorporation of pol polyprotein into foamy virus capsids.

Authors:  Martin Heinkelein; Cordula Leurs; Matthias Rammling; Katrin Peters; Helmut Hanenberg; Axel Rethwilm
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.